Entrada Therapeutics Reports First Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: May 8, 2025
– Receives regulatory authorization in the EU for ELEVATE-44-201, a Phase 1/2 MAD clinical study of ENTR-601-44 in patients living with Duchenne muscular dystrophy who are amenable to exon 44 skipping –
Read more at globenewswire.comNASDAQ:TRDA (12/19/2025, 2:53:06 PM)
11.065
+0.1 (+0.96%)
Find more stocks in the Stock Screener
